Study of tenapanol hydrochloride in the reduction of excessive fluid retention (e.g. oedema) in peritoneal dialysis patients.

Study on the possibility of correcting the excess of fluid volume in patients undergoing peritoneal dialysis with the use of Tenapanol

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031250075

Enrollment

Registered

2025-04-30

Start date

2025-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney failure during peritoneal dialysis Chrnoic kidney failure

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients who are 20 years of age or older at the time of consent 2) Patients undergoing peritoneal dialysis on an outpatient basis 3) Patients whose hyperphosphatemia is being corrected by hyperphosphatemia medications (replacement of existing hyperphosphatemia medications) 4) Patients for whom written consent to participate in this study is obtained from the patient or a surrogate.

Exclusion criteria

Exclusion criteria: 1) Patients on hybrid dialysis with hemodialysis

Design outcomes

Primary

Measure	Time frame
Extracellular fluid volume by impedance method	—

Secondary

Measure	Time frame
edema, body weight, blood pressure, average daily dehydration (2 weeks before outpatient), daily urine output, chest x-ray (cardiothoracic ratio) , serum creatinine, serum electrolytes, blood gases, HANP, IVC diameter by echo, right atrial diameter, LVEF, Other medications for hyperphosphatemia, laxative dosage, VitD usage, Bristol Stool Scale	—

Contacts

Public ContactShigeyoshi Horinaka

Department of Nephrology, Dokkyo Medical University Saitama Medical center

ayoshino@dokkyomed.ac.jp+81-489651111

Outcome results